{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"30"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"30"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"3"}],"units":"Participants"}],"description":"Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.","groups":[{"description":"Participants self-administered oral pemigatinib 1/2/4 milligrams (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG000","title":"Part 1: Intermittent Pemigatinib 1/2/4 mg QD"},{"description":"Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG001","title":"Part 1: Intermittent Pemigatinib 6 mg QD"},{"description":"Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG002","title":"Parts 1 and 2: Intermittent Pemigatinib 9 mg QD"},{"description":"Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG003","title":"Parts 1 and 2: Intermittent Pemigatinib 13.5 mg QD"},{"description":"Participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG004","title":"Part 1: Intermittent Pemigatinib 20 mg QD"},{"description":"Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG005","title":"Parts 1 and 2: Continuous Pemigatinib 9 mg QD"},{"description":"Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG006","title":"Parts 1 and 2: Continuous Pemigatinib 13.5 mg QD"},{"description":"Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG007","title":"Parts 1 and 2: Continuous Pemigatinib 20 mg QD"},{"description":"Participants self-administered oral pemigatinib 7.5 mg twice daily (BID) on Days 1 through 21 of each 21-day cycle.","id":"OG008","title":"Part 1: Continuous Pemigatinib 7.5 mg BID"},{"description":"Participants self-administered oral pemigatinib 10 mg BID on Days 1 through 21 of each 21-day cycle.","id":"OG009","title":"Part 1: Continuous Pemigatinib 10 mg BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population: all enrolled participants who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"up to 763 days","title":"Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)","type":"PRIMARY","unitOfMeasure":"Participants"}